Pharma marketers today are under increasing pressure to prove the impact of their campaigns. Traditional performance metrics only scratch the surface. Strategy teams are often left without the full picture of how messages are landing with Healthcare Professionals (HCPs).
In a recent LinkedIn Live session, Talking Medicines Co-Founder Scott Crae and Product Owner Josh Eadsforth discussed how using AI in the analysis of HCP analytics is giving Pharma teams a clearer understanding of message alignment, engagement, and campaign performance. By applying Advanced Data Science and AI to real-world HCP and Patient conversations, marketers can move from assumptions to actionable insights. Here are some of the key themes from the session.
Understanding Mindsets, Not Just Job Titles
Not all HCPs respond to campaigns in the same way. Scott explained two common HCP personas that influence engagement: the Visionary and the Traditionalist.
Visionaries are energized by innovation and new clinical data. Traditionalists focus on established evidence and long-term outcomes. By understanding which messages resonate with each mindset, marketers can tailor content that aligns with how different HCPs make decisions.
Verbatims Add Context to Data
Real-world HCP conversations provide an essential layer of insight. Talking Medicines curates health-related data to unlock how different personas react to messaging themes. For example, a Visionary might describe moving away from conventional care pathways. A Traditionalist may raise concerns about limited data and clinical risk.
Tracking Message Alignment Over Time
Campaign performance rarely stays the same. Talking Medicines maps HCP sentiment across key stages of the campaign including before, during, and after launch. This allows teams to track how alignment shifts as the campaign progresses.
By pairing verbatims with message alignment scores, Pharma marketers can clearly see where engagement increases, where it holds steady, and where it declines. These insights make it possible to adjust strategies based on evidence rather than assumptions.
Adapting to Market Shifts in Real Time
Campaigns do not operate in a vacuum. Competitor activity, new regulatory guidelines, and evolving clinical data can all influence how HCPs and patients respond.
Talking Medicines helps brands stay ahead by continuously monitoring real-world narratives. Teams can identify emerging themes, reframe their messaging, and maintain relevance even as the market changes.
This approach results in:
-
-
A clear understanding of what is driving engagement
-
Confident and informed decision-making
-
The ability to quantify HCP alignment and track campaign impact with clarity
-
The confidence to answer the question every marketer faces: Has it worked?
-
Why AI Built for Pharma Delivers More
Talking Medicines’ Drug-GPT is purpose-built for life sciences. Through Advanced Data Science and AI, Drug-GPT curates unstructured real-world, health-related data to deliver meaningful intelligence that meets compliance standards.
Rather than offering surface-level analytics, Drug-GPT enables marketers to understand who is engaging, how they are responding, and why it matters. These insights support every stage of the brand journey, from pre-launch preparation to navigating loss of exclusivity.
Watch the Full Session On-Demand
For those who missed it live, you can catch the full conversation
To get in touch or explore how this can apply to your brand, reach out to Scott directly to book time in hereÂ
